Tepotinib
Tepmetko (tepotinib) is a small molecule pharmaceutical. Tepotinib was first approved as Tepmetko on 2021-02-03. The pharmaceutical is active against hepatocyte growth factor receptor. Tepmetko's patents are valid until 2030-03-19 (FDA).
| Trade Name | Tepmetko |
|---|---|
| Common Name | Tepotinib |
| Indication | |
| Drug Class | Tyrosine kinase inhibitors |
